Vascular memory: Can we broaden the concept of the metabolic memory?

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Jermendy, György ^a  

^a BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

Author keywords

Cardiovascular diseases; Metabolic legacy; Metabolic memory; Vascular memory

Indexed keywords

ANTIDIABETIC AGENT; ATENOLOL; ATORVASTATIN; CAPTOPRIL; ENALAPRIL; HEMOGLOBIN A1C; INSULIN; METFORMIN; NITRENDIPINE; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TRANDOLAPRIL; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FOLLOW UP; GENE EXPRESSION; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIFESTYLE MODIFICATION; MICROALBUMINURIA; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTOLIC HYPERTENSION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; EARLY INTERVENTION; LIFESTYLE; METABOLISM; PHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; EARLY MEDICAL INTERVENTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; LIFE STYLE; METABOLIC PHENOMENA;

EID: 84862190650     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-44     Document Type: Review

References (74)

1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zimmet B, . Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group Intensive treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. 2637991, 16371630, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.
2. Ceriello A, Ihnat MA, Thorpe JE. The " metabolic memory" : is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 2009, 94:410-415. 10.1210/jc.2008-1824, 19066300.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
4. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
5. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999, 22:99-111. 2745938, 10333910, Epidemiology of Diabetes Interventions and Complications (EDIC).
6. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000, 342:381-389. 2630213, 10666428, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
7. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008, 126:1707-1715. 2663518, 19064853.
8. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569. 10.1001/jama.287.19.2563, 2622728, 12020338, Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
9. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, . Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011, 171:412-420. 10.1001/archinternmed.2011.16, 3085024, 21403038, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group.
10. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B, . The DCCT/EDIC Research Group Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011, 365:2366-2376. 3270008, 22077236, The DCCT/EDIC Research Group.
11. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL, . DCCT/EDIC Research Group Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006, 29:340-344. 10.2337/diacare.29.02.06.dc05-1549, 2622720, 16443884, DCCT/EDIC Research Group.
12. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM, . Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010, 33:1090-1096. 10.2337/dc09-1941, 2858182, 20150297, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
13. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH, . DCCT/EDIC Research Group Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119:2886-2893. 10.1161/CIRCULATIONAHA.108.837369, 2757005, 19470886, DCCT/EDIC Research Group.
14. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S, . Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348:2294-2303. 2701300, 12788993, Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group.
15. Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, Nathan DM, . DCCT/EDIC Research Group Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2011, 60:607-613. 10.2337/db10-0296, 3028362, 21270271, DCCT/EDIC Research Group.
16. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, Zinman B, Jacobson A, Sun W, Lachin JM, Nathan DM, . DCCT/EDIC Research Group The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006, 55:3556-3565. 10.2337/db06-0653, 2701297, 17130504, DCCT/EDIC Research Group.
17. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study Group.
18. The Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet 1994, 344:1383-1389. The Scandinavian Simvastatin Survival Study Group.
19. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K, Wedel H. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4 S) of cholesterol lowering. Am J Cardiol 2000, 86:257-262. 10.1016/S0002-9149(00)00910-3, 10922429.
20. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4 S). Lancet 2004, 364:771-777. 10.1016/S0140-6736(04)16936-5, 15337403.
21. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
22. Heart Protection Study Collaborative Group Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011, 378:2013-2020. 3242163, 22115874, Heart Protection Study Collaborative Group.
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307. 10.1056/NEJM199511163332001, 7566020.
24. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007, 357:1477-1486. 10.1056/NEJMoa065994, 17928595.
25. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group.
26. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002, 359:1379-1387. Erratum: Lancet 2002, 360:1430, The long-term intervention with pravastatin in ischaemic disease (LIPID) study group.
27. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, . ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158. 10.1016/S0140-6736(03)12948-0, 12686036, ASCOT investigators.
28. Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, Mehlsen J, Nieminen MS, O'Brien ET, Ostergren J, . ASCOT Investigators The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008, 29:499-508. 10.1093/eurheartj/ehm583, 18175773, ASCOT Investigators.
29. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, . ASCOT Investigators The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J 2011, 32:2525-2532. 10.1093/eurheartj/ehr333, 21873710, ASCOT Investigators.
30. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153. The Heart Outcomes Prevention Evaluation Study Investigators.
31. Bosch J, Lonn E, Pogue J, Arnold MO, Dagenais GR, Yusuf S, . HOPE/HOPE-TOO Study Investigators Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE Study Extension. Circulation 2005, 112:1339-1346. HOPE/HOPE-TOO Study Investigators.
32. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676. 10.1056/NEJM199512213332503, 7477219.
33. Buch P, Rasmussen S, Abildstrom SZ, Køber L, Carlsen J, Torp-Pedersen C. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 2005, 26:145-152.
34. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691. Erratum in: N Engl J Med 1992, 327:1768, The SOLVD Investigators.
35. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003, 361:1843-1848. 10.1016/S0140-6736(03)13501-5, 12788569.
36. Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G, McCormack P, Nachev C, O'Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004, 22:847-857. 10.1097/00004872-200404000-00029, 15126928.
37. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998, 317:703-713. UK Prospective Diabetes Study Group.
38. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008, 359:1565-1576. 10.1056/NEJMoa0806359, 18784091.
39. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, . Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. 10.1056/NEJM200105033441801, 11333990, Finnish Diabetes Prevention Study Group.
40. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, . Finnish Diabetes Prevention Study Group Sustained reduction in the incidence of type 2 diabetes by lifestyle-intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679. 10.1016/S0140-6736(06)69701-8, 17098085, Finnish Diabetes Prevention Study Group.
41. Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J, . Finnish Diabetes Prevention Study Group Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study-secondary analysis of the randomized trial. PLoS One 2009, 4:e5656. 10.1371/journal.pone.0005656, 2682577, 19479072, Finnish Diabetes Prevention Study Group.
42. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544. 10.2337/diacare.20.4.537, 9096977.
43. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789. 10.1016/S0140-6736(08)60766-7, 18502303.
44. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, . Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. 1370926, 11832527, Diabetes Prevention Program Research Group.
45. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM, . Diabetes Prevention Program Research Group 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. 10.1016/S0140-6736(09)61457-4, 3135022, 19878986, Diabetes Prevention Program Research Group.
46. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393. 10.1056/NEJMoa021778, 12556541.
47. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591. 10.1056/NEJMoa0706245, 18256393.
48. Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005, 1:93-106. 10.2174/1573399052952631, 18220586.
49. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008, 14:962-968. 10.2174/138161208784139729, 18473846.
50. Yan SF, Ramasamy R, Bucciarelli LG, Wendt T, Lee LK, Hudson BI, Stern DM, Lalla E, DU Yan S, Rong LL, Naka Y, Schmidt AM. RAGE and its ligands: a lasting memory in diabetic complications?. Diab Vasc Dis Res 2004, 1:10-20. 10.3132/dvdr.2004.001, 16305050.
51. Ihnat MA, Thorpe JE, Kamat CD, Szabó C, Green DE, Warnke LA, Lacza Z, Cselenyák A, Ross K, Shakir S, Piconi L, Kaltreider RC, Ceriello A. Reactive oxygen species mediate a cellular " memory" of high glucose stress signalling. Diabetologia 2007, 50:1523-1531. 10.1007/s00125-007-0684-2, 17508197.
52. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008, 205:2409-2417. Erratum in: J Exp Med 2008, 205:2683, 10.1084/jem.20081188, 2556800, 18809715.
53. Siebel AL, Fernandez AZ, El-Osta A. Glycemic memory associated epigenetic changes. Biochem Pharmacol 2010, 80:1853-1859. 10.1016/j.bcp.2010.06.005, 20599797.
54. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010, 6:665-675. 10.1038/nrendo.2010.188, 21045787.
55. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010, 299:F14-F25. 10.1152/ajprenal.00200.2010, 2904177, 20462972.
56. Reddy MA, Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res 2011, 90:421-429. 10.1093/cvr/cvr024, 3096305, 21266525.
57. Villeneuve LM, Natarajan R. Epigenetic mechanisms. Contrib Nephrol 2011, 170:57-65.
58. Schisano B, Tripathi G, McGee K, McTernan PG, Ceriello A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011, 54:1219-1226. 10.1007/s00125-011-2049-0, 21287141.
59. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM, . DCCT Skin Collagen Ancillary Study Group Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111. 10.2337/diabetes.54.11.3103, 2622724, 16249432, DCCT Skin Collagen Ancillary Study Group.
60. Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia 2010, 53:1093-1098. 10.1007/s00125-010-1706-z, 20237754.
61. Jax TW. Metabolic memory: a vascular perspective. Cardiovasc Diabetol 2010, 9:51. 10.1186/1475-2840-9-51, 2946275, 20836897.
62. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005, 96(5A):24F-33F. 2684977, 16126020.
63. Elrod JW, Lefer DJ. The effects of statins on endothelium, inflammation and cardioprotection. Drug News Perspect 2005, 18:229-236. 10.1358/dnp.2005.18.4.908656, 16034478.
64. Parati G, Bilo G, Ochoa JE. Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies. Diabetes Care 2011, 34(Suppl 2):S297-S303.
65. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158. 10.1097/HJH.0b013e328333146d, 19838131.
66. Ismail H, Mitchell R, McFarlane SI, Makaryus AN. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep 2010, 10:32-36. 10.1007/s11892-009-0081-y, 20425064.
67. Volpe M, Cosentino F, Tocci G, Palano F, Paneni F. Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. Curr Hypertens Rep 2011, 13:318-324. 10.1007/s11906-011-0205-z, 21487737.
68. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindström J, Tuomilehto J, . Finnish Diabetes Prevention Study Group Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 2003, 52:2532-2538. 10.2337/diabetes.52.10.2532, 14514637, Finnish Diabetes Prevention Study Group.
69. de Mello VD, Lindström J, Eriksson J, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Sundvall J, Laakso M, Tuomilehto J, Uusitupa M. Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: the Finnish Diabetes Prevention Study. Diabetes Care 2012, 35:211-217. 10.2337/dc11-1272, 22210578.
70. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the " metabolic memory" , the new challenge of diabetes. Diabet Med 2007, 24:582-586. 10.1111/j.1464-5491.2007.02138.x, 17490424.
71. Ceriello A. Hypothesis: the " metabolic memory" , the new challenge of diabetes. Diabetes Res Clin Pract 2009, 86S:S2-S6.
72. Jermendy G. Late effect of treatment for reducing cardiovascular risk - a hypothesis on cardiometabolic therapeutic memory. Med Hypotheses 2009, 73:73-79. 10.1016/j.mehy.2009.01.034, 19329258.
73. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 2009, 52:1219-1226. 10.1007/s00125-009-1352-5, 19373446.
74. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011, 378:156-167. 10.1016/S0140-6736(11)60698-3, 3136726, 21705063.